SRH Wald-Klinikum Gera

Hospital


Location: Gera, Germany (DE) DE

ISNI: 0000000102147565

ROR: https://ror.org/00q236z92

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Implementation of Current ENETS Guidelines for Surgery of Small (2cm) Pancreatic Neuroendocrine Neoplasms in the German Surgical Community: An Analysis of the Prospective DGAV StuDoQ|Pancreas Registry (2019) Mintziras I, Keck T, Werner J, Fichtner-Feigl S, Wittel U, Senninger N, Vowinkel T, et al. Journal article Cetuximab in combination with platinum-based chemotherapy or radiotherapy in patients with recurrent and/or metastatic SSCHN in clinical routine: Updated interim results of the prospective SOCCER study (2018) Hecht M, Hahn D, Wolber P, Hautmann M, Reichert D, Weniger J, Belka C, et al. Conference contribution Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto (2018) Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching P, Lederer B, et al. Journal article Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First 400 Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry (2018) Lee M, Wlodarczak A, Bennett J, Torzewski J, Haude M, Vrolix M, Buck T, et al. Conference contribution Influence of previous Radiotherapy on the Success of an immune-oncologic Therapy in metastatic Melanoma - a retrospective multicenter Study of ADO (2018) Knispel S, Zimmer L, Gutzmer R, Heinzerling L, Weishaupt C, Pfoehler C, Gesierich A, et al. Conference contribution Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto) (2017) Untch M, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, et al. Conference contribution Prognostic factors and outcomes in metastatic uveal melanoma treated with PD-1 or combined PD-1 / CTLA-4 inhibition (2017) Heppt M, Heinzerling L, Kaehler K, Forschner A, Kirchberger M, Loquai C, Meissner M, et al. Conference contribution Interleukin-2 and Checkpoint Inhibition as a successful Therapy Sequence for metastatic Melanoma: Case Report and retrospective Analysis in 52 Patients (2017) Cosgarea , Zimmer L, Weide B, Gutzmer R, Heinzerling L, Weishaupt C, Pfoehler C, et al. Conference contribution Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition (2017) Heppt MV, Heinzerling L, Kaehler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, et al. Journal article Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years (2017) Weyerer V, Schneckenpointner R, Filbeck T, Burger M, Hofstaedter F, Wild PJ, Fine SW, et al. Journal article
1 ... 3 4 5 6 7